MarketPulse

psoriasis

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oruka Therapeutics Raises $700M in Upsized Public Offering at $72.50 Per Share

Oruka Therapeutics prices 9.66M shares at $72.50 in upsized offering, raising $700.4M with potential additional proceeds from underwriter overallotment option.
ORKAmonoclonal antibodyclinical-stage
BenzingaBenzinga··Not Specified

Oruka Therapeutics Plans $500M Capital Raise via Public Offering

Oruka Therapeutics plans $500M public offering plus $75M underwriter option to fund monoclonal antibody pipeline for psoriasis and inflammatory conditions.
ORKAmonoclonal antibodypublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

90+ Companies Racing to Transform Psoriasis Treatment Landscape

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.
SNGXTAKFBLGCANFALMS+1clinical trialsbiologics
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Showcases Dermatology Pipeline Momentum With Early-Relief Data at AAD 2026

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.
NVSchronic spontaneous urticariaimmunology